Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 8931-230
Fax: +49 (0)711 - 8931-323
send an Email


Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 1999: 81/5 (May) pp.668-852
Pages: 668-672

Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review

Bernd-Jan Sanson (1) , Anthonie W. A. Lensing (1) , Martin H. Prins (2) , Jeffrey S. Ginsberg (3) , Zinoviy S. Barkagan (4) , Edith Lavenne-Pardonge (5) , Benjamin Brenner (6) , Mordechay Dulitzky (7) , Jørn D. Nielsen (8) , Zoltan Boda (9) , Susanna Tu
From the (1) Department of Vascular Medicine and (2) Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands; (3) Department of Medicine, McMaster University, Hamilton, Ontario, Canada; (4) Siberian Reg


Unfractionated heparin (UFH) remains the anticoagulant of choice during pregnancy. Low-molecular-weight heparins (LMWH) are an attractive alternative to UFH due to their logistic advantages and their association with a lower incidence of osteoporosis and HIT. We reviewed all published clinical reports concerning the use of LMWH during pregnancy. In addition, participants of an international interest group contributed a cohort of pregnant women treated with LMWH. Pregnancies were divided into two groups; those with and those without maternal comorbid conditions. The number of adverse fetal outcomes and the occurrence of maternal complications were evaluated in the two groups. In the group of women with comorbid conditions (n = 290), 13.4% of the pregnancies were associated with an adverse fetal outcome. In contrast, in the group of women without comorbid conditions (n = 196), 3.1% were associated with an adverse outcome, which is comparable to that seen in the normal population. We conclude that LMWH appear to be a safe alternative to unfractionated heparin as an anticoagulant during pregnancy.